Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoGenix has received a notice of allowance for a patent on its herpes composition from the US Patent and Trademark Office. The allowed patent claims both the composition of matter utilizing the company's single-stranded DNA expression vector technology and methods of treatment utilizing the therapeutic compound.
Subscribe to our email newsletter
While most pharmacological agents are employed to chemically signal cells to interrupt, reduce production or bind and regulate specific disease-causing proteins, this application of Cytogenix’s novel single-stranded DNA (ssDNA) technology directs infected cells to make a short nucleic acid sequence that specifically targets and impedes the activity of a herpes virus protein needed for viral reproduction, the company said.
Cindee Ewell, CytoGenix patent counsel, said: “Grant of this patent in the US provides a major step forward in validating the use of our ssDNA expression technology in DNA-based therapeutics and should provide support for allowance of other company patent applications utilizing similar technology.”